CLC
RECOMMENDS PROMPT APPOINTMENT
OF DIRECTOR OF ONCOLOGY PRODUCTS
(November 5, 2004)
November 5, 2004
Via Telecopy
Lester M. Crawford, D.V.M., Ph.D.
Acting Commissioner
Food and Drug Administration
5600 Fishers Lane
Room 1471- Parklawn Bldg.
Rockville, Maryland 20857
Dear Dr. Crawford:
The undersigned organizations have been engaged in discussions with officials of the Food and Drug Administration (FDA) over the course of the past several years in support of a reorganization of the agency to provide better review and regulation of products to prevent, diagnose, and treat cancer. We were pleased when FDA announced in July 2004 that a new Office of Oncology Drug Products would be established within the Center for Drug Evaluation and Research (CDER), and we are now writing about the appointment of the Director of the new Office.
The success of the
new Office and enhancement of cancer product review will depend significantly
on the qualifications and qualities of the new Director. We realize that
FDA has the ability to tailor its search and appointment process to ensure
that the new Director has the skills that are necessary for this important
position. We are pleased that FDA has made commitments to include outside
experts as part of the selection panel for this position and to recruit
a seasoned cancer clinical researcher. As the process for recruiting and
evaluating candidates moves forward, we urge FDA to retain as a basic
qualification that the Director be a board certified medical oncologist
or hematologist with substantial experience in designing and conducting
cancer clinical trials. Beyond these fundamental qualifications, the new
Director should have the administrative and leadership skills necessary
to ensure the smooth functioning of the Office and to attract a critical
mass of oncologists to complete the important work of the Office.
Because we have been engaged in discussions about the Office for a number
of years and can see the potential for positive results from it, we have
a great sense of urgency about the appointment of the new Director. We
urge FDA to move with all deliberate speed to evaluate candidates from
inside and outside the agency who possess the necessary qualifications
to make the Office a success.
Thank you for your consideration of our views on this important matter.
Sincerely,
Cancer Leadership
Council
American Society of Clinical Oncology
American Society for Therapeutic Radiology & Oncology, Inc.
Cancer Care, Inc.
Cancer Research and Prevention Foundation
The Children's Cause for Cancer Advocacy
Coalition of National Cancer Cooperative Groups
International Myeloma Foundation
Kidney Cancer Association
The Leukemia & Lymphoma Society
Lymphoma Research Foundation
Multiple Myeloma Research Foundation
National Coalition for Cancer Survivorship
North American Brain Tumor Coalition
Sarcoma Foundation of America
The Susan G. Komen Breast Cancer Foundation
Us Too International Prostate Cancer Education and Support Network
The Wellness Community
Y-ME National Breast Cancer Organization
cc: Janet Woodcock,
M.D.
Acting Deputy Commissioner for Operations
About CLC | What's New | Policy
Issues | Participants' Login
Home | Sitemap | Contact Info
Copyright
© 2001-2002 Cancer Leadership Council. All rights reserved.
Please send comments and suggestions to webmaster@cancerleadership.org.